“Whether it’s our family, our friends, all of us are potentially patients one day.”
In a single sentence, Dr. Anthony Coyle, senior vice president and chief scientific officer at Pfizer’s Centers for Therapeutic Innovation (CTI), sums up what inspires the researchers and scientists fueling progress at America’s biopharmaceutical companies.
CTI’s unique model allows Pfizer scientists to work side-by-side with academia, patient foundations and the National Institutes of Health (NIH) to bridge the gap between early scientific discovery and its translation into new medicines. The research teams identify promising, early stage projects then collaborate to create and test potential new medicines.
While the road to scientific discovery is long and often full of set-backs, collaboration across the research and development ecosystem has the potential to make continual advancements – that ultimately lead to breakthrough discoveries – that much more efficient.
Through CTI’s network of 25 academic medical centers, five foundations, and the NIH, Pfizer is helping transform the traditional model of drug discovery in hopes that patients will realize the benefits of new life-changing and life-saving medicines even more quickly.
Learn more about the CTI and how this innovative approach translates into real progress and hope for patients.
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004
Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
"1. Information Collection."